Zereunesay Desta
Overview
Explore the profile of Zereunesay Desta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
249
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robarge J, Desta Z, Nguyen A, Li L, Hertz D, Rae J, et al.
Breast Cancer Res Treat
. 2016 Dec;
161(3):453-461.
PMID: 27943008
Purpose: Inter-individual differences in estrogen concentrations during treatment with aromatase inhibitors (AIs) may contribute to therapeutic response and toxicity. The aim of this study was to determine plasma concentrations of...
2.
Kadakia K, Snyder C, Kidwell K, Seewald N, Flockhart D, Skaar T, et al.
Oncologist
. 2016 Mar;
21(5):539-46.
PMID: 27009936
Background: Early discontinuation of aromatase inhibitors (AIs) is common and leads to poor outcomes but is challenging to predict. In the Exemestane and Letrozole Pharmacogenetics trial, a high rate of...
3.
Henry N, Azzouz F, Desta Z, Li L, Nguyen A, Lemler S, et al.
J Clin Oncol
. 2012 Feb;
30(9):936-42.
PMID: 22331951
Purpose: Aromatase inhibitors (AIs) are effective for treatment of hormone receptor-positive breast cancer, but adherence and persistence with therapy are poor. Predictors of treatment discontinuation are not clearly defined. It...
4.
Henry N, Rae J, Li L, Azzouz F, Skaar T, Desta Z, et al.
Breast Cancer Res Treat
. 2009 Jan;
117(3):571-5.
PMID: 19153830
Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a...